Physician profile
Victor C Ching
NPI 1356334437
$808,982.79
in general payments reported to CMS, 2019-2025
28 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $533K · 2021: $118K · 2022: $72.25 · 2023: $240 · 2024: $22K · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $24K · Food and Beverage: $661 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $23,730.93 |
| Food and Beverage | $661.19 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $532,285.97 | 2020 | |
| Medtronic, INC. | $141,553.77 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Medtronic USA, INC. | $98,930.07 | 2019-2020 | |
| Medtronic Vascular, INC. | $34,266.88 | 2019 | |
| Astellas Pharma US INC | $365.62 | 2019-2023 | Xtandi |
| Abbvie INC. | $309.85 | 2019-2021 | |
| Procept Biorobotics Corporation | $194.87 | 2025 | |
| Boston Scientific Corporation | $161.59 | 2019-2022 | |
| Pfizer INC. | $143.31 | 2019-2020 | |
| Urogen Pharma, INC. | $130.95 | 2023 | Jelmyto |
| Olympus America INC. | $127.55 | 2025 | Bovie, Soltive |
| Telix Pharmaceuticals | $83.57 | 2025 | Illuccix |
| Endo Pharmaceuticals INC. | $83.21 | 2019-2020 | |
| Axonics, INC. | $78.18 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $37.49 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.26 | 2019 | |
| Antares Pharma, INC. | $21.62 | 2021 | |
| Blue Earth Diagnostics | $20.95 | 2020 | |
| Pelvital USA, INC. | $20.61 | 2025 | |
| Travere Therapeutics, INC. | $19.68 | 2020 | |
| Allergan, INC. | $18.49 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $18.18 | 2019 | |
| Cook Medical LLC | $17.40 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.02 | 2019 | |
| Coloplast Corp | $15.99 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.07 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.44 | 2021 | |
| Janssen Biotech, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.